An Introduction to Cataract Surgery
Cataract surgery is one of the most common surgical procedures globally, and the numerous advances over recent years have helped to improve patient outcomes. Femtosecond laser-assisted cataract surgery (FLACS) introduced surgeons to a new non-invasive technique with high reproducibility compared with conventional procedures. Innovations in IOL technology, including most recently the introduction of extended depth of focus lenses and accommodating IOLs, offer more options for patients and better refractive outcomes along with shorter recovery times.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Cataract Surgery Content
Eric Donnenfeld, Hawaiian Eye and Retina 2021: Next-generation Extended Depth of Focus Intraocular Lenses
It was a pleasure to speak with Eric Donnenfeld (Ophthalmic Consultants of Long Island, NY, USA) about advantages and limitations of new extended depth of focus intraocular lenses and the future of this technology. Questions What factors need to be considered when selecting an extended depth of focus (EDOF) intraocular lens (IOL) for a patient […]
Eric Donnenfeld, Hawaiian Eye and Retina 2021: Extended Depth of Focus Intraocular Lenses Following Cataract Surgery
We were delighted to speak to Eric Donnenfeld (Ophthalmic Consultants of Long Island, NY, USA) about limitations of multifocal intraocular lenses (IOLs) following cataract surgery, and how extended depth of focus IOLs have overcome these limitations. Questions What are the limitations of multifocal intraocular lenses (IOLs) following cataract surgery? (00:16) How have extended depth of […]
Antibiotic Stewardship in Ophthalmic Clinical Practice
Since the introduction of antibiotics, bacterial resistance has continued to pose an ongoing problem across all infectious diseases,1 and ocular infection pathogens are no exception. Antibiotic resistance in ophthalmology has become an important global health issue. A total of 4.5 million cataract surgeries are performed each year.2 These carry a risk of postoperative infection, particularly endophthalmitis, a severe sight-threatening inflammation of the eye.3,4 As a result, a number of common antibiotics are prescribed to prevent infections.5 Since up to 97% of ophthalmologists use post-operative antibiotics, this is equivalent to 61 million days per year of antibiotic exposure.6 Antibiotics are also used in the treatment of common ophthalmic infections such as acute infective conjunctivitis, which is one of the most common issues encountered in primary care and constitutes a significant healthcare burden.7 Antimicrobial resistance, which develops naturally through gene mutations, has been identified as a major healthcare threat worldwide, largely due to overuse and misuse of antibiotics. The presence of antibiotic resistance among ocular pathogens is a major concern, as it complicates the choice of antibiotic and may lead to treatment failure.8 The need for responsible use of antibiotics is increasingly recognised, and in recent years, the concept of antimicrobial stewardship has developed. Antibiotic stewardship has been defined in a consensus statement from the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, and the Pediatric Infectious Diseases Society as ‘coordinated interventions designed to improve and measure the appropriate use of [antibiotic] agents by promoting the selection of the optimal [antibiotic] drug regimen including dosing, duration of therapy, and route of administration’.9 Santen have recently launched the Re-SOLVE Antibiotic Resistance initiative, which aims to promote antibiotic stewardship by recommending a set of actions which encourage the sustainable and effective use of antibiotics, including selection of an antibiotic therapy.10 In an expert interview, Mr Ali Mearza describes the aims of the RE-SOLVE initiative. Q. Could you tell us a little about the aims of the Re-SOLVE antibiotic initiative? The campaign launched in October 2020 and was dedicated to the importance and benefits of sustainable antibiotic use in ophthalmology.10 The Re-SOLVE campaign aims to rapidly and responsibly raise awareness of the threat of antibiotic resistance in ophthalmology; catalyse an environment of urgent action and antibiotic stewardship in the ophthalmology community; and promote awareness of, and access to, medical education opportunities and networks of helpful experts. Q. What practical advice would you give to ophthalmologists in terms of the use of prophylactic antibiotics during and after cataract surgery, and infectious complications such as endophthalmitis? During cataract surgery, there is now good evidence to support the use of povidone-iodine in the conjunctival sac prior to the commencement of surgery, followed by intracameral antibiotic (either cefuroxime or moxifloxacin) at the end of surgery.11,12 This has been showed to lower the incidence of endophthalmitis significantly. Following surgery, a short course of antibiotic x4/day for a week, makes more sense rather than a prolonged 4-week course as is the case still in many centres. Q. What is the importance of selecting a therapy with short duration to minimise antibiotic use in everyday practice? Short-term therapy (1 week) may be enough post-operatively as an additional measure above using povidone-iodine and intracameral antibiotics during cataract surgery. Additionally, no tapering – these two factors could positively impact the lowering antibiotic exposure and slow down the development of antibiotic resistance. Q. How else can ophthalmologists select antibiotic therapies that will minimise antibiotic use in everyday practice? It is important that, where possible, the most appropriate antibiotic is selected and used for the shortest duration of time possible. Most departments work closely with their microbiology colleagues to develop guidelines on the most appropriate use of antibiotics and these should be reviewed yearly in line with changes in antibiotic resistance. Antibiotics should not be used where not indicated, and ongoing training and education will help instil the message of appropriate use for the next generation of ophthalmologists. References World Health Organisation. Antimicrobial resistance. Available at: www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance (accessed 4 November 2020). Eurostat. Cataract surgery: how countries compare. Available at: https://ec.europa.eu/eurostat/web/products-eurostat-news/-/DDN-20190108-1 (accessed 4 November 2020). Gower EW, Lindsley K, Tulenko SE, et al. Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery. Cochrane Database Syst Rev. 2017;2:Cd006364. Garg P, Roy A, Sharma S. Endophthalmitis after cataract surgery: epidemiology, risk factors, and evidence on protection. Curr Opin Ophthalmol. 2017;28:67–72. ESCRS Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery: Data, Dilemmas and Conclusions 2013. Available at: www.escrs.org/downloads/Endophthalmitis-Guidelines.pdf (accessed 4 November 2020). Haripriya A. Antibiotic prophylaxis in cataract surgery – An evidence-based approach. Indian J Ophthalmol. 2017;65:1390–5. Ryder EC, Benson S. Conjunctivitis. [Updated 2020 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available at: Available from: www.ncbi.nlm.nih.gov/books/NBK541034/ (accessed 4 November 2020). Asbell PA, DeCory HH. Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. PLoS One. 2018;13:e0205814. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of america and the society for healthcare epidemiology of America. Clin Infect Dis. 2016;62:e51–77. Santen joins forces with ophthalmologists in the fight against antibiotic resistance. Available at: www.santen.eu/our-vision/emea-news/santen-joins-forces-ophthalmologists-fight-against-antibiotic-resistance (accessed 4 November 2020). Ahmed Y, Scott IU, Pathengay A, et al. Povidone-iodine for endophthalmitis prophylaxis. Am J Ophthalmol. 2014;157:503–4. Titiyal JS, Kaur M. Role of intracameral antibiotics in endophthalmitis prophylaxis following-cataract surgery. Indian J Ophthalmol. 2020;68:688–91. Author profile: Mr Ali Mearza is Director and founding partner of Ophthalmic Consultants of London, UK. He is also the Clinical Director of Ophthalmology at London’s Imperial College Healthcare NHS Trust, London, the UK’s first Academic Health Sciences Centre. His specialist interests are in laser and lens vision correction techniques, cataract surgery and corneal transplantation. He has a keen interest in clinical research and has over 30 peer-reviewed publications to his name and is an invited journal reviewer. His publications range from case reports, book chapters, clinical reviews and studies looking at new techniques and technologies. Many of his surgical techniques are featured on his YouTube channel which has over 300 000 views to date. He’s also featured in the media with television appearances on the Discovery Channel as well in mainstream media publications. Disclosures: Ali Mearza has nothing to disclose in relation to this expert interview. Support: Commissioned, edited and supported by Touch Medical Media, who commissioned the interview in liaison with Santen. Writing assistance was provided by Katrina Mountfort from Touch Medical Media. Published: 27 January 2021
How are novel IOL technologies increasing the range of vision after cataract surgery?
Watch leading expert Dr John Hovanesian discuss advances in intraocular lens (IOL) technologies and how novel IOLs help meet the needs and preferences of individual patients after cataract surgery.
- Understand the rationale for novel intraocular lens (IOL) technologies designed to meet patients’ visual needs (near, intermediate and distant)
- Discuss the differentiating features of novel IOL technologies and implications for patient satisfaction
- Review the available evidence for novel IOL technologies and how this translates to IOL selection in clinical practice
Jorge L Alió, EGS 2020 – Innovations in Premium IOLs
We caught up with Jorge L. Alió (Miguel Hernández University of Alicante, Elche, Spain) to find out the most promising recent advances in premium IOLs. Questions Could you give us a brief overview of your experience with premium IOLs? (0:05) What are the most promising recent advances and what issues with premium IOLs remain to […]
Cynthia Matossian, AAO 2020 – Outcomes With Dexamethasone Intraocular Suspension 9% and Concomitant Postoperative Anti-inflammatory Medications
It was a huge pleasure to catch up with our esteemed Editorial Board member, Cynthia Matossian (Matossian Eye Associates, Hopewell and Hamilton, NJ, USA), as she talked us through her AAO presentation on outcomes with dexamethasone intraocular suspension 9% and concomitant postoperative anti-inflammatory medications. Questions What is the rationale for the use of dexamethasone intraocular […]
Optimal Injection Techniques for Best Dexamethasone Intraocular Suspension Instillation Results
Watch leading experts discuss the use of intracameral corticosteroids for the management of inflammation following cataract surgery.
- Describe the unmet needs in post-operative care for patients undergoing cataract surgery
- Identify which patients might benefit most from the use of dexamethasone intraocular suspension
- Describe the key efficacy and safety data available for dexamethasone intraocular suspension
- Understand the optimal techniques to use for successful instillation of dexamethasone intraocular suspension
John A Hovanesian, AAO 2020 – The D3 Study
It was a pleasure to speak with our valued Editorial Board member, John A Hovanesian (Harvard Eye Associates, Laguna Hills, CA, USA), about his AAO 2020 poster presentation on the D3 study, evaluating dexamethasone intraocular suspension versus prednisolone acetate 1%. Questions What are the challenges of topical medications after cataract surgery? (00:06) Could you tell […]
The personalized patient experience in nAMD: What do the latest data tell us about optimizing clinical management?
Stay abreast of the latest research on the clinical management of neovascular age-related macular degeneration (nAMD) for individual patients by watching a webinar and interviews with international experts reviewing data from the virtual proceedings of the World Ophthalmology Congress 2020 (WOC2020 Virtual). Part 1: Watch internationally renowned expert Prof. Pravin Dugel review key data from WOC2020 Virtual Part 2: Choose from leading experts who discuss what the data findings mean for global and regional practice
- Evaluate strategies for the management of retinal fluid in nAMD
- Interpret results from clinical trials and real-world experience to inform on optimal dosing of anti-VEGF in nAMD
- Recall factors that contribute to optimization of clinical management and reduction in treatment burden for patients with nAMD
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!